Executive Summary Most biotechnology companies believe their greatest risk is clinical failure. In reality, many significantly reduce shareholder value long before a Phase III trial fails. They overestimate market opportunity, build organizations that exceed commercial demand, and commit fixed costs that future revenue cannot support. Marinus Pharmaceuticals provides an important case study. The company ultimately faced multiple challenges, including clinical setbacks, financing pressures, and commercial realities. This article does not…
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
